Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors

2017 ◽  
Vol 165 (3) ◽  
pp. 743-750 ◽  
Author(s):  
Carol A. Parise ◽  
Vincent Caggiano
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Subtypes ◽  
Node Negative ◽  
Cancer Subtypes ◽  
Her2 Breast Cancer ◽  
Risk Of Mortality

scholarly journals The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Carol A. Parise ◽  
Vincent Caggiano
Keyword(s):  
Breast Cancer ◽  
American Indians ◽  
White Women ◽  
Ethnic Disparities ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
Her2 Breast Cancer ◽  
Risk Of Mortality ◽  
Race Ethnicity ◽  
Racial Ethnic

Background. The eight ER/PR/HER2 breast cancer subtypes vary widely in demographic and clinicopathologic characteristics and survival. This study assesses the contribution of SES to the risk of mortality for blacks, Hispanics, Asian/Pacific Islanders, and American Indians when compared with white women for each ER/PR/HER2 subtype.Methods. We identified 143,184 cases of first primary female invasive breast cancer from the California Cancer Registry between 2000 and 2012. The risk of mortality was computed for each race/ethnicity within each ER/PR/HER2 subtype. Models were adjusted for tumor grade, year of diagnosis, and age. SES was added to a second set of models. Analyses were conducted separately for each stage.Results. Race/ethnicity did not contribute to the risk of mortality for any subtype in stage 1 when adjusted for SES. In stages 2, 3, and 4, race/ethnicity was associated with risk of mortality and adjustment for SES changed the risk only in some subtypes. SES reduced the risk of mortality by over 45% for American Indians with stage 2 ER+/PR+/HER2− cancer, but it decreased the risk of mortality for blacks with stage 2 triple negative cancer by less than 4%.Conclusions. Racial/ethnic disparities do not exist in all ER/PR/HER2 subtypes and, in general, SES modestly alters these disparities.

Breast cancer subtypes in Chinese Americans: A study from the Mount Sinai Health System.

2014 ◽  
Vol 32 (26_suppl) ◽  
pp. 39-39
Author(s):  
Camila Masias ◽  
Theresa H. Shao
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Chinese Americans ◽  
Breast Cancer Subtypes ◽  
Age At Diagnosis ◽  
Chinese Patients ◽  
Breast Cancers ◽  
Cancer Subtypes ◽  
Her2 Breast Cancer ◽  
Mount Sinai

39 Background: Breast cancer has been increasing in many Asian countries, as well as among Asian Americans. While many studies have examined breast cancer subtypes in African American and Caucasian populations, few have looked at tumor subtypes in the Asian population. We aimed to examine breast cancer subtypes in Chinese Americans. Methods: We identified all Chinese patients diagnosed with invasive breast cancers between 2005 and 2012 from the Cancer Registry of Mount Sinai Beth Israel, Mount Sinai St. Luke’s, and Roosevelt Hospitals. The following clinical data were collected for each patient: age at diagnosis, year of diagnosis, largest tumor size (cm), lymph node status, estrogen receptor (ER), progesterone receptor (PR) and HER2 status. Based on ER, PR, and HER2, patients were categorized into three molecular subtypes: 1) Hormone receptor (HR)+ (ER and/or PR positive, HER2 negative), HER2+ and triple negative (TN) (ER, PR, and HER2 negative). Descriptive variables were analyzed using one-way Anova test. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated from logistic regression models. Results: There were 175 Chinese patients diagnosed with invasive breast cancers from 2005 to 2012. Median age at diagnosis was 54 (range 27-90). One hundred fourteen (65%) were HR+, 41 (23%) were HER2+, and 20 (11%) were TN. There were 59 (34%) patients diagnosed at age ≤ 50 and twelve patients (7%) were diagnosed at age < 40. There were more HER2+ and TN breast cancers diagnosed in women age ≤ 50 compared to age > 50, but the difference was not statistically significant. Women in the HR+ group were diagnosed at an older age compared to the other two subgroups (57 ± 12, 52 ± 8, and 52 ± 10 for HR+, HER2+, and TN, respectively, p = 0.036). Patients with TN breast cancers were more likely to have lymph node involvement compared to HR+ or HER2+ patients (p = 0.02). There was a trend of increasing prevalence of HER2+ breast cancer observed in recent years: 18.5% in 2005-2006, 23.8% in 2007-2008, 18.4% in 2009-2010, and 29.8% in 2011-2012. Conclusions: We observed a high proportion of breast cancer among young Chinese Americans as well as an increasing prevalence of HER2+ breast cancer in this population in recent years. Further studies are warranted.

Omega-3 fatty acids and ERPR(-) and HER2/neu(+/-) breast cancer prevention.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. TPS1589-TPS1589
Author(s):  
Chidimma Kalu ◽  
Sarah Woelke ◽  
Jianying Zhang ◽  
Martha Belury ◽  
Rulong Shen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fatty Acids ◽  
Adipose Tissue ◽  
Fatty Acid ◽  
Corn Oil ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
Her2 Breast Cancer ◽  
Breast Adipose Tissue ◽  
Breast Adipose

TPS1589 Background: The most aggressive breast cancer subtypes tend to be estrogen and progesterone receptor negative (ERPR(-)) and human epidermal growth factor receptor type 2 positive (HER2(+)). Women with these breast cancer subtypes (triple negative, ERPR(-)HER2(+)) tend to experience worse clinical outcomes and have a relatively higher risk of recurrence. Our previous research demonstrated that dietary omega-3 (n-3) fatty acids can significantly inhibit ERPR(-) HER2(+) tumorigenesis in MMTV-HER2/neu transgenic mice fed fish oil vs corn oil-based diets. The fish oil diet group developed 30% fewer breast tumors, had lower Ki67 expression, and experienced less mammary atypia relative to the corn oil diet group. Other studies involving diet, nutrition and breast cancer point to the potentially protective effect of an anti-inflammatory diet on the risk of developing ER(-) and HER2(+) breast cancer, further supporting the evidence that the ERPR(-), HER2(±) subtypes may be highly responsive to this bioactive nutrient. Methods: This is a double-blinded, randomized clinical trial of high dose (~5.4 g EPA+DHA) vs low dose (~0.9 g EPA+DHA in fatty acid mix of the typical American diet) of n-3 fatty acids in breast cancer survivors of ERPR(-), HER2(±) breast cancer. Eligible participants will take 5 capsules/day for 12 months, with cellular samples of breast epithelial and/or adipose tissue obtained by fine needle aspirations of the contralateral breast. The study aims to determine whether n-3 fatty acid supplementation will modify fatty acid metabolite content in breast adipose tissue, modulate cytomorphology and/or cell proliferation in breast epithelial cells, affect DNA methylation patterns, and modulate pro- vs anti-inflammatory gene expression patterns in breast adipose tissue. Correlative aims will evaluate possible associations between factors such as breast adipose tissue, red cell membrane fatty acid profiles, BMI, and reported dietary intake. Sample size of 40 participants per arm was calculated to provide at least 80% power to detect a statistically significant difference for each primary endpoint. This study focuses on women survivors of high risk breast cancer subtypes, specifically triple negative or ERPR(-)HER2(+) disease, who are currently without long term adjuvant options. Eligibility criteria include prior diagnosis of ERPR(-) stage 0 to III breast cancer, ≤5 years from completion of standard therapy.The study was closed to accrual in November 2018; less than 9 months of follow-up remain for active study participants. Clinical trial information: NCT02295059.

scholarly journals Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes

Cell Systems ◽  
2018 ◽  
Vol 6 (3) ◽  
pp. 329-342.e6 ◽  
Author(s):  
Spencer S. Watson ◽  
Mark Dane ◽  
Koei Chin ◽  
Zuzana Tatarova ◽  
Moqing Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Subtypes ◽  
Mechanisms Of Resistance ◽  
Cancer Subtypes ◽  
Her2 Breast Cancer

scholarly journals BRIP1 overexpression is correlated with clinical features and survival outcome of luminal breast cancer subtypes

2018 ◽  
Vol 7 (1) ◽  
pp. 65-77 ◽  
Author(s):  
Ishita Gupta ◽  
Allal Ouhtit ◽  
Adil Al-Ajmi ◽  
Syed Gauhar A Rizvi ◽  
Hamad Al-Riyami ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Subtypes ◽  
Luminal Breast Cancer ◽  
Dual Function ◽  
Potential Candidate ◽  
Cancer Subtypes ◽  
Her2 Breast Cancer ◽  
Potential Biomarker ◽  
Tumor Stages

In Oman, breast cancer is most common, representing approximately more than 25% of all cancers in women. Relatively younger populations of patients (25–40 years) present surprisingly with an aggressive phenotype and advanced tumor stages. In this study, we investigated differential gene expressions in Luminal A, Luminal B, triple-negative and Her2+ breast cancer subtypes and compared data to benign tumor samples. We identified a potential candidate gene BRIP1, showing differential expression in the four breast cancer subtypes examined, suggesting that BRIP1 has the profile of a useful diagnostic marker, suitable for targeted therapeutic intervention. RT-qPCR and Western blotting analysis showed higher BRIP1 expression in luminal samples as compared to triple-negative subtype patient’s samples. We further screened BRIP1 for eventual mutations/SNPs/deletions by sequencing the entire coding region. Four previously identified polymorphisms were detected, one within the 5′-UTR region (c.141-64G > A) and three in the BRCA-binding domain (c.2755T > C, c.2647G > A and c.3411T > C). Kaplan–Meier analysis revealed that patients with overexpression of BRIP1 displayed a poor survival rate (P < 0.05). BRIP1 has a dual function of an oncogene and a tumor suppressor gene in addition to its role as a potential biomarker to predict survival and prognosis. Data obtained in this study suggest that BRIP1 can plausibly have an oncogenic role in sporadic cancers.

scholarly journals Differences in Breast Cancer Subtypes Among Racial/Ethnic Groups

2021 ◽  
Author(s):  
Surbhi Bansil ◽  
Anthony Silva ◽  
Corinne Jones ◽  
Elena Hidalgo ◽  
Ian Pagano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ethnic Groups ◽  
Breast Cancer Subtype ◽  
Cancer Prognosis ◽  
Breast Cancer Subtypes ◽  
Her2 Receptor ◽  
Cancer Subtypes ◽  
Her2 Breast Cancer ◽  
Cancer Subtype ◽  
Racial Ethnic

Abstract PurposeDifferences in incidence of breast cancer subtypes among racial/ethnic groups have been evaluated as a contributing factor in the disparities seen in breast cancer prognosis. We evaluated new breast cancer cases in Hawaii to determine if there were subtype differences according to race/ethnicity that may contribute to known disparities.MethodsWe reviewed 4,318 cases of women diagnosed with breast cancer from two large tumor registries between 2013-2020. We evaluated the new breast cancer cases according to age at diagnosis, self-reported race, and breast cancer subtype (ER, PR, and HER2 receptor status).ResultsWe found both premenopausal and postmenopausal Native Hawaiian women were less likely to be diagnosed with triple negative breast cancer (OR=0.33, P=0.009; OR=0.62, P=0.03 respectively). Premenopausal Japanese women were 71% less likely to be diagnosed with triple positive (ER+/PR+/HER2+) breast cancer (OR=0.29, P=0.0003). Postmenopausal Filipino women were 89% more likely to be diagnosed with ER-/PR-/HER2+ breast cancer (OR=1.89, P=0.02). ConclusionsResults of our study support that there are racial/ethnic differences in breast cancer subtypes among our population which may contribute to the differences in outcome seen. Further evaluation of other clinical and pathological features in each breast cancer subtype may inform potential mechanisms for outcome disparities seen among different racial/ethnic groups.

Sign in / Sign up

Export Citation Format

Share Document